Last 36 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.44 | 0.40 | 0.48 | 0.52 | 0.31 | 0.42 | 0.29 | 0.99 | 1.60 | 1.47 | 1.67 | 1.79 | 2.90 | 5.66 | 11.53 | 13.46 | 18.72 | 15.07 | 32.87 | 34.35 | 84.41 |
| — | -4.7% | +65.0% | -47.7% | -80.7% | -71.6% | -82.6% | -44.8% | -44.7% | -73.9% | -85.5% | -86.7% | -84.5% | -62.5% | -64.9% | -60.8% | -77.8% | -88.9% | -80.8% | +9943.8% | +50370.9% | |
| P/B Ratio | 0.14 | 0.41 | 0.34 | 0.37 | 0.18 | 0.25 | 0.16 | 0.91 | 0.80 | 0.57 | 0.71 | 0.80 | 0.91 | 0.91 | 1.48 | 1.77 | 1.92 | 1.41 | 2.41 | 2.57 | 4.60 |
| — | +66.0% | +119.8% | -59.5% | -77.0% | -56.4% | -77.9% | +14.1% | -12.3% | -37.5% | -52.1% | -54.9% | -52.6% | -35.4% | -38.6% | -31.0% | -58.3% | -76.6% | -59.9% | +1551.0% | +4497.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 22.0% | 52.8% | 48.6% | 42.7% | 45.7% | 51.6% | 45.5% | 41.9% | -139.1% | 33.3% | 32.2% | 22.7% | 29.5% | 26.6% | 27.9% | 22.0% | 25.1% | 22.1% | 15.1% | 3.8% | 24.8% |
| — | +2.2% | +6.9% | +2.1% | +132.9% | +55.2% | +41.3% | +84.1% | -571.4% | +24.8% | +15.4% | +3.5% | +17.8% | +20.8% | +84.7% | +479.4% | +1.1% | -40.9% | -54.1% | -87.2% | -26.0% | |
| Operating Margin | -116.9% | -88.3% | -118.1% | -107.4% | -115.9% | -115.8% | -131.1% | -146.3% | -722.9% | -219.0% | -354.9% | -186.9% | -1215.0% | -436.5% | -510.4% | -456.8% | -445.2% | -480.9% | -525.7% | -456.7% | -444.2% |
| — | +23.7% | +9.9% | +26.6% | +84.0% | +47.1% | +63.1% | +21.7% | +40.5% | +49.8% | +30.5% | +59.1% | -172.9% | +9.2% | +2.9% | -0.0% | -0.2% | -12.6% | -49.2% | -63.8% | +4.6% | |
| Net Margin | -92.6% | -90.8% | -124.2% | -99.8% | -115.4% | -101.8% | -48.0% | -246.5% | -728.6% | -208.8% | -358.3% | -409.4% | -1208.0% | -449.2% | -500.7% | -470.8% | -440.5% | -482.1% | -525.8% | -364.2% | -445.8% |
| — | +10.8% | -158.5% | +59.5% | +84.2% | +51.2% | +86.6% | +39.8% | +39.7% | +53.5% | +28.4% | +13.0% | -174.2% | +6.8% | +4.8% | -29.3% | +1.2% | +1.0% | -67.5% | -23.9% | +9.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.2% | -21.5% | -20.3% | -16.8% | -17.9% | -14.7% | -7.4% | -47.8% | -68.5% | -19.9% | -35.1% | -40.8% | -67.5% | -17.4% | -15.4% | -14.6% | -11.2% | -10.8% | -9.2% | -6.8% | -6.0% |
| — | -46.6% | -173.1% | +64.8% | +73.9% | +26.3% | +78.9% | -17.1% | -1.5% | -14.1% | -127.5% | -180.1% | -500.6% | -61.6% | -67.1% | -115.4% | -86.0% | -103.5% | -84.8% | +85.7% | +94.3% | |
| ROA | -35.1% | -13.2% | -12.0% | -10.4% | -11.0% | -8.9% | -4.0% | -24.5% | -40.8% | -11.3% | -16.9% | -22.1% | -49.7% | -13.8% | -12.4% | -12.3% | -9.9% | -9.6% | -8.3% | -6.2% | -5.8% |
| — | -48.7% | -200.0% | +57.6% | +73.1% | +21.4% | +76.3% | -10.8% | +17.8% | +18.2% | -36.3% | -80.7% | -403.8% | -43.8% | -49.9% | -96.7% | -70.2% | -89.6% | -84.9% | +73.0% | +81.6% | |
| ROIC | -49.1% | -14.4% | -13.3% | -11.4% | -10.2% | -9.4% | -10.9% | -15.4% | -41.2% | -12.6% | -17.8% | -11.9% | -55.7% | -12.6% | -11.5% | -10.8% | -9.1% | -8.5% | -7.2% | -8.2% | -14.5% |
| — | -52.7% | -21.9% | +26.1% | +75.2% | +25.4% | +38.7% | -29.6% | +26.1% | +0.1% | -54.9% | -10.1% | -514.3% | -48.7% | -58.8% | -31.4% | +37.5% | +90.1% | +87.7% | +87.8% | +84.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.21 | 0.45 | 0.16 | 0.35 | 0.43 | 0.38 | 0.77 | 0.46 | 0.34 | 0.46 | 0.83 | 0.09 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | — |
| — | -50.8% | +18.8% | -79.8% | -24.8% | +25.7% | -16.5% | -6.6% | +439.1% | +591.2% | +848.0% | +1665.2% | +131.1% | +31.4% | +35.1% | +47.5% | — | — | -12.9% | -93.2% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.98 | 2.48 | 1.84 | 1.98 | 2.12 | 1.76 | 1.70 | 1.06 | 1.43 | 1.63 | 1.46 | 1.40 | 2.60 | 3.66 | 3.74 | 4.38 | 6.51 | 7.75 | 12.99 | 12.47 | 19.32 |
| — | +40.4% | +7.9% | +87.1% | +49.0% | +8.3% | +16.3% | -24.5% | -45.2% | -55.5% | -60.9% | -68.0% | -60.1% | -52.8% | -71.2% | -64.9% | -66.3% | -75.7% | -74.9% | +138.5% | +1537.7% | |
| Quick Ratio | 1.74 | 1.96 | 1.59 | 1.74 | 1.82 | 1.41 | 1.34 | 0.76 | 0.99 | 1.11 | 1.13 | 1.17 | 1.94 | 2.69 | 2.87 | 3.55 | 5.77 | 7.01 | 12.12 | 11.89 | 18.81 |
| — | +39.3% | +18.4% | +129.2% | +83.3% | +27.3% | +18.7% | -35.2% | -49.0% | -58.9% | -60.7% | -67.0% | -66.3% | -61.6% | -76.3% | -70.1% | -69.4% | -77.7% | -76.3% | +144.7% | +1791.6% | |
| Interest Coverage | -87.35 | — | -114.18 | -108.69 | -122.03 | -92.79 | -35.41 | -744.33 | -649.32 | -213.55 | -218.71 | -7.97 | -1583.89 | -524.39 | -487.13 | -490.63 | -434.36 | -433.01 | -387.87 | -138.40 | -10359.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BNGO stock.
Bionano Genomics, Inc.'s current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bionano Genomics, Inc.'s current operating margin is -116.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bionano Genomics, Inc.'s business trajectory between earnings reports.